Literature DB >> 7391606

A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement).

R P Haydey, M Patarroyo de Rojas, I Gigli.   

Abstract

Levels in serum of components of complement were studied in a group of 10 patients with mixed cryoglobulinemia. The profiles found in most patients showed decreased levels of the early complement components C1, C4, and C2, with normal levels of C3. Experiments performed to define the mechanism(s) responsible for this unusual complement profile showed that activation of the early complement components in serum was due to the activation of the classical pathway by mixed cryoglobulins. They also showed that the characteristic lack of effect on C3 was due to the action of a previously unrecognized regulatory mechanism upon C3 convertase of the classical pathway mediated by 2 normal serum proteins, namely, the C4 binding protein (C4-bp) and the C3b inactivator (C3bINA).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7391606     DOI: 10.1111/1523-1747.ep12543575

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease.

Authors:  Qing-Mei Zou; Xiao-Hui Li; Rui-Xia Song; Nan-Ping Xu; Ting Zhang; Ming-Ming Zhang; Yao Lin; Lin Shi; Jin Fu; Xiao-Dai Cui
Journal:  Pediatr Res       Date:  2015-05-04       Impact factor: 3.756

3.  Anti-C1q antibodies in hepatitis C virus infection.

Authors:  D Saadoun; S Sadallah; M Trendelenburg; N Limal; D Sene; J C Piette; J A Schifferli; P Cacoub
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 4.  Reappraisal of the clinical expression of mixed cryoglobulinemia.

Authors:  G Montagnino
Journal:  Springer Semin Immunopathol       Date:  1988

5.  Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; F Moosig; A Gause; K Herlyn; E Csernok; H Hansen; W L Gross
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 6.  The kidney in mixed cryoglobulinemias.

Authors:  D J Cordonnier; J C Renversez; P Vialtel; E Dechelette
Journal:  Springer Semin Immunopathol       Date:  1987

7.  Soluble C3 proconvertase and convertase of the classical pathway of human complement. Conditions of stabilization in vitro.

Authors:  M B Villiers; N M Thielens; M G Colomb
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

Review 8.  The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia.

Authors:  Ahmed El-Shamy; Andrea D Branch; Thomas D Schiano; Peter D Gorevic
Journal:  Front Immunol       Date:  2018-05-29       Impact factor: 7.561

Review 9.  Rheumatoid factor, complement, and mixed cryoglobulinemia.

Authors:  Peter D Gorevic
Journal:  Clin Dev Immunol       Date:  2012-08-26

10.  Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component.

Authors:  F C de Beer; M L Baltz; S Holford; A Feinstein; M B Pepys
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.